# **QIBA Diffusion-Weighted Imaging MR Biomarker Committee (BC) Call**

Thursday, July 16, 2020 at 2 p.m. (CT) Call Summary

#### Participants

Michael Boss, PhD (Co-chair) Dariya Malyarenko, PhD (Co-chair) Edson Amaro, MD Rajpaul Attariwala, MD, PhD Thomas Chenevert, PhD Amita Shukla Dave, PhD Daniel Margolis, MD Felipe Nascimento, MD Nancy Obuchowski, PhD Savannah Partridge, PhD Mark Shiroishi, MD Joe Koudelik Susan Stanfa

**RSNA** 

Moderator: Dr. Boss

#### **Review of Previous Call Summary**

• The notes from the June 18, 2020 DWI BC t-con were approved as presented

### DWI BC Leadership Changes are Official (Drs. Boss and Malyarenko)

- Dr. Boss reported that Dr. Chenevert had stepped down from his DWI BC Co-chair role, in which he has served since the inception of this group
  - He has made many significant contributions to QIBA efforts, including the management of a DWI groundwork project that informed the Profile, and as the MR Scientific Liaison on the Steering Committee
  - $\circ$   $\;$  He plans to continue his involvement as a member of the DWI BC  $\;$
  - Dr. Malyarenko was welcomed as a new DWI BC Co-chair; it was noted she has a strong understanding of DWI work to be done and has been the point-of-contact with the VERDICT team
- Dr. Boss thanked Drs. Chenevert and Malyarenko for their valuable contributions

# Update on Brazil DWI efforts, technical confirmation conversation redux (Drs. Boss, Amaro and Obuchowski)

- Drs. Nascimento and Amaro recently contacted Dr. Boss regarding their RSNA R&E grant exploring implementation of the DWI Profile in São Paulo, Brazil
- The phantom and clinical data they have collected may be enough to help advance the DWI Profile to Stage 3: technical confirmation, at least for the brain disease site
- There were substantive differences in imaging protocols across disease sites, as well as differences in b value and echo time and repetition time
- Brief background on the project was provided, and it will be presented in greater depth during the Aug. call
  - 478 human subjects and the QIBA ADC phantom were scanned at 17 different sites with 1.5T and 3T MR platforms; a comparison was done to assess variability
  - $\circ$   $\;$  The same subjects were scanned on multiple vendor platforms for a subset of cases
  - Challenges included temperature issues in phantoms and position ROIs
  - o Working at a large hospital with government connections facilitated involving so many sites in this study
- In reference to their draft final reports, Drs. Amaro and Nascimento may have demonstrated the feasibility of the DWI Profile's brain protocol
- Advancement to stage 3 requires drafting a checklist and sending it to 2-3 sites to determine whether the requirements are feasible; it is also necessary to demonstrate that conformance activities in Section 4: Assessment Procedures, of the Profile can be performed
- This could be a possible model for other Profiles to achieve technical confirmation, and with modification, possibly claim confirmation

- Additional discussion needed re: a path forward for Profiles with disease site-specific Claims
  - o Patient data are critical to demonstrate the feasibility of the Profile
  - Obtaining funding for test-retest studies is a challenge
  - Dr. Boss noted how useful the R&E grant mechanism has been to advance the DWI Profile effort to this advanced stage; grant funding was used to collect test/retest data
  - The DWI BC is hopeful that data can be obtained from additional institutions re: disease sites other than brain; there may be a prospect for an additional study in Brazil
  - Collaboration with the VERDICT team and experience with ACRIN 6701 provides encouragement that the prostate protocol is achievable
  - o ISPY-2 data from ACRIN 6698 may provide breast data

## White Paper (Dr. Boss)

- Dr. Boss is leading the effort to draft a white paper to inform the public about the DWI Profile, promote QIBA DWI BC efforts, and better engage the radiology community
- The outline was circulated for feedback prior to this call
- The plan is to model the paper after Kinahan PE, et al. <u>QIBA Profile for FDG-PET/CT as an Imaging Biomarker</u> <u>Measuring Response to Cancer Therapy</u>
  - $\circ$   $\;$  The manuscript was a digestible summary of the various FDG-PET Profile sections
  - It was noted in the paper that the Technically Confirmed Claims were informed by a review of the literature, but were not independently verified by a prospective study that conformed to the Profile
- Although there was concern voiced regarding the number of similar QIBA member-driven papers that *Radiology* would be willing to publish, the DWI BC intends to submit this paper to *Radiology*, with *JMRI* as back-up
- The content will include the history of the DWI Profile and its development
  - First, a literature search was conducted on all disease sites; responsibilities were divided among volunteers to review the publications for test-retest data
  - There were not enough test-retest data on breast to include this disease site when the Profile was published as Stage 2: Public Comment; once the required data were made available, content was added, a second round of public comment ensued, the Profile was edited in response and the updated version was published
  - The challenge posed by the lack of test-retest literature and metrics will be highlighted and the white paper effort led by Dr. Dave: <u>Quantitative imaging biomarkers alliance (QIBA) recommendations for improved</u> <u>precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials</u>, will be referenced
  - New repeatability studies currently exist and should be noted in the paper, since these were not referenced in Dr. Dave's original white paper
- As a next step, suggestion to insert sections of the DWI Profile, circulate the draft, and ask DWI members for feedback

# Discussion on VERDICT team data/collaboration, next steps (Dr. Malyarenko)

- The DWI BC has been in contact with a research team in the UK, led by Dr. Shonit Punwani, that developed a promising quantitative technique for prostate diffusion MRI called VERDICT
  - This approach yields a QIB called the intracellular volume fraction (FIC), which they compared to ADC in a test-retest study published in *Radiology*
  - Dr. Malyarenko has spearheaded the collaboration with their team to encourage a companion publication that reports on this work using wCV rather than the ICC repeatability metric employed in their original publication

- The DWI BC and VERDICT team have discussed prospective DWI data acquisition, which could provide ADC testretest data to confirm the DWI claim
  - The MR CC and RSNA staff who had previously inquired about the collaboration were informed of this effort
  - In combination with the ACRIN 6701 study, there may now be sufficient data to refine the prostate claim, and better support the existing claim with additional literature
- Dr. Malyarenko reported that next steps with VERDICT have been defined; she will provide offline updates as more information becomes available
- Discussion with MR CC Co-chairs, and perhaps EC/SC needed re: this pathway/opportunity for acquiring claim confirmation data; it was noted that no other QIBA group has achieved stage 4

## Extended BC Call Schedule for August and September (RSNA Staff, all)

- In lieu of F2F breakout sessions that typically occur during QIBA Annual Meetings, BCs were offered the opportunity to extend their calls from 1 to 2-hours starting in July, until the Sept 29 virtual QIBA Annual Meeting
- The DWI BC will have extended calls in Aug and Sept to focus on strategy for Stage 3: Technical Confirmation

### **Next Steps**

- Drs. Amaro and Nascimento will discuss results with Dr. Obuchowski prior to the Aug call
  - Feedback from DWI BC members was encouraged; this will help Drs. Amaro and Nascimento to develop their presentation for the next call, which will focus more in-depth on their work
- Staff will Doodle for some 2-hour blocks in mid-Aug and mid-Sept in case the more time than usual is needed
- Dr. Boss to insert sections of the DWI Profile into the white paper, circulate the draft, and ask DWI members for feedback/additions to the document
  - o Staff to circulate Kinahan paper for reference
  - The Dave paper will also be distributed to help DWI BC members to avoid duplicating information and address gaps in that already-published work

### Next DWI-MR BC Call: TBD, based on DWI BC member availability for a 2-hour long call

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at <u>QIBA@RSNA.org</u> if their attendance is not reflected on the call summaries.